Companies › Pentixapharm
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| [90Y]Y-PentixaTher Yttrium-90 labelled sigma-1 receptor ligand for endoradiotherapy | SIGMAR1 | Phase 1 | CNS Lymphoma | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06132737 | [90Y]Y-PentixaTher | Phase 1 | CNS Lymphoma | Oncology | Sep 2027 |
Exciva UCB BIOSCIENCES Anavex Life Sciences Zogenix CSPC Ouyi Pharmaceutical
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.